Short answer
Dyne Therapeutics, Inc. (DYN) filed an 8-K current report with the SEC on July 22, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $375.2M gross equity offering from 18.3M shares at $20.50 per share.
Dyne Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $375.2M gross equity offering from 18.3M shares at $20.50 per share
- Approximately $352.1M net proceeds, increasing to $405.0M if the 2.745M-share option is fully exercised
- Company-only share sale, creating material dilution for existing shareholders
- Proceeds provide substantial additional funding for Dyne’s operations and development programs
- Underwriter option expires 30 days after July 21, 2026; closing expected July 23, 2026
Item 8.01 · Other Events
- Public offering pricing announced July 21, 2026; transaction details reside in Exhibit 99.1
- Offering proceeds plus existing liquidity and $50.0M Hercules term-loan tranche expected to fund operations through second quarter 2028
- Runway estimate excludes potential milestone-based Hercules tranches and future product revenue
- Key risks include offering-closing conditions, clinical outcomes, regulatory approval, debt covenants, and required interest and principal payments
Item EX-99.1 · Exhibit EX-99.1
- $375.15M gross proceeds from 18.3M shares priced at $20.50 each
- Potential additional $56.27M proceeds from underwriters’ 2.745M-share, 30-day option
- All shares sold by Dyne, creating material equity dilution for existing shareholders
- Capital supports clinical-stage DMD and DM1 programs plus preclinical FSHD, Pompe, and DMD mutation programs
- Offering expected to close July 23, 2026, subject to customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dyne Therapeutics, Inc. 8-K filings
Get the next DYN 8-K as it lands
Follow DYN for push alerts, or ask the research agent what this filing means.